Potential of circulating pro‐angiogenic microRNA expressions as biomarkers for rapid angiographic stenotic progression and restenosis risks in coronary artery disease patients underwent percutaneous coronary intervention

This study aimed to investigate the correlation of pro‐angiogenic microRNA (miRNA) expressions with rapid angiographic stenotic progression (RASP) and restenosis risks in coronary artery disease (CAD) patients underwent percutaneous coronary intervention (PCI) with drug‐eluting stents (DES).

[1]  Y. Ba,et al.  Exosome-Derived miR-130a Activates Angiogenesis in Gastric Cancer by Targeting C-MYB in Vascular Endothelial Cells. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  Jie Hao,et al.  Circulating pro-angiogenic micro-ribonucleic acid in patients with coronary heart disease. , 2018, Interactive cardiovascular and thoracic surgery.

[3]  Fachao Zhi,et al.  MiR-218 regulates epithelial–mesenchymal transition and angiogenesis in colorectal cancer via targeting CTGF , 2018, Cancer Cell International.

[4]  M. Tariq,et al.  Understanding the role of non-coding RNA (ncRNA) in stent restenosis. , 2018, Atherosclerosis.

[5]  O. Agbulut,et al.  MiRroring the Multiple Potentials of MicroRNAs in Acute Myocardial Infarction , 2017, Front. Cardiovasc. Med..

[6]  J. Xing,et al.  Circulating pro-angiogenic and anti-angiogenic microRNA expressions in patients with acute ischemic stroke and their association with disease severity , 2017, Neurological Sciences.

[7]  F. Martelli,et al.  Overexpression of miR-210 and its significance in ischemic tissue damage , 2017, Scientific Reports.

[8]  A. Abhari,et al.  Cardioprotective Effect of Crocin Combined with Voluntary Exercise in Rat: Role of Mir-126 and Mir-210 in Heart Angiogenesis , 2017, Arquivos brasileiros de cardiologia.

[9]  Wang Lq,et al.  The expression research of miR-210 in the elderly patients with COPD combined with ischemic stroke. , 2016 .

[10]  S. Schrepfer,et al.  miR-126: a potential new key player in hypoxia and reperfusion? , 2016, Annals of translational medicine.

[11]  A. Orekhov,et al.  The role of miR-126 in embryonic angiogenesis, adult vascular homeostasis, and vascular repair and its alterations in atherosclerotic disease. , 2016, Journal of molecular and cellular cardiology.

[12]  E. Edelman,et al.  Pathology of Endovascular Stents. , 2016, Interventional cardiology clinics.

[13]  R. Schnabel,et al.  miRNA-197 and miRNA-223 Predict Cardiovascular Death in a Cohort of Patients with Symptomatic Coronary Artery Disease , 2015, PloS one.

[14]  B. Fleischmann,et al.  Intercellular transfer of miR-126-3p by endothelial microparticles reduces vascular smooth muscle cell proliferation and limits neointima formation by inhibiting LRP6. , 2017, Journal of molecular and cellular cardiology.

[15]  B. Fu,et al.  High concentrations of uric acid inhibit angiogenesis via regulation of the Krüppel-like factor 2-vascular endothelial growth factor-A axis by miR-92a. , 2015, Circulation journal : official journal of the Japanese Circulation Society.

[16]  T. Rabelink,et al.  The Role of microRNA-126 in Vascular Homeostasis. , 2015, Current vascular pharmacology.

[17]  L. Nelin,et al.  MKP‐1 is a target of miR‐210 and mediate the negative regulation of miR‐210 inhibitor on hypoxic hPASMC proliferation , 2015, Cell biology international.

[18]  E. van Rooij,et al.  Inhibition of miR-92a improves re-endothelialization and prevents neointima formation following vascular injury , 2014, Cardiovascular research.

[19]  N. Weintraub,et al.  miR-92a inhibits vascular smooth muscle cell apoptosis: role of the MKK4–JNK pathway , 2014, Apoptosis.

[20]  F. Kiessling,et al.  MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1 , 2014, Nature Medicine.

[21]  J. Hata,et al.  Epidemiology of stroke and coronary artery disease in Asia. , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[22]  N. de Las Heras,et al.  Pathophysiology of Vascular Remodeling in Hypertension , 2013, International journal of hypertension.

[23]  N. Renna,et al.  Role of Renin-Angiotensin System and Oxidative Stress on Vascular Inflammation in Insulin Resistence Model , 2013, International journal of hypertension.

[24]  X. Niu,et al.  miR-210 activates notch signaling pathway in angiogenesis induced by cerebral ischemia , 2012, Molecular and Cellular Biochemistry.

[25]  Y. Hayashi,et al.  Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. , 2012, Circulation.

[26]  Laura Mauri,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Circulation.

[27]  G. Levine,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Journal of the American College of Cardiology.

[28]  Jin-qing Yuan,et al.  Increased plasma C-reactive protein level predicts rapid progression of non-target atherosclerotic lesions in patients with stable angina after stenting. , 2011, Chinese medical journal.

[29]  F. Eberli,et al.  Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents: Results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE Trial , 2011, Circulation.

[30]  J. Moses,et al.  Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial. , 2010, JACC. Cardiovascular interventions.

[31]  Iva Nikolic,et al.  EGFL7 meets miRNA-126: an angiogenesis alliance , 2010, Journal of angiogenesis research.

[32]  G. Stone,et al.  The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of "oculostenotic" reintervention in patients with intermediate lesions. , 2010, JACC. Cardiovascular interventions.

[33]  Guohong Li,et al.  Role of specific microRNAs for endothelial function and angiogenesis. , 2009, Biochemical and Biophysical Research Communications - BBRC.

[34]  D. Srivastava,et al.  MicroRNAs: Opening a New Vein in Angiogenesis Research , 2009, Science Signaling.

[35]  S. Umemura,et al.  C-reactive protein elevation and rapid angiographic progression of nonculprit lesion in patients with non-ST-segment elevation acute coronary syndrome. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[36]  Fabio Martelli,et al.  MicroRNA-210 Modulates Endothelial Cell Response to Hypoxia and Inhibits the Receptor Tyrosine Kinase Ligand Ephrin-A3* , 2008, Journal of Biological Chemistry.

[37]  Seung‐Jung Park,et al.  Long‐term clinical outcomes after sirolimus‐eluting stent implantation for treatment of restenosis within bare‐metal versus drug‐eluting stents , 2008, Catheterization and cardiovascular interventions.

[38]  Joshua T. Mendell,et al.  MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1 , 2008, Proceedings of the National Academy of Sciences.

[39]  Simon Wandel,et al.  Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.

[40]  J. Granada,et al.  Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. , 2007, JAMA.

[41]  M. Hochadel,et al.  Drug-eluting stents versus bare metal stents following rotational atherectomy for heavily calcified coronary lesions: late angiographic and clinical follow-up results. , 2007, Journal of interventional cardiology.

[42]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.

[43]  T. Vassiliades,et al.  Integrated coronary revascularization with drug-eluting stents: immediate and seven-month outcome. , 2006, The Journal of thoracic and cardiovascular surgery.

[44]  J. Stanik-Hutt,et al.  Drug‐coated Stents: Preventing Restenosis in Coronary Artery Disease , 2004, The Journal of cardiovascular nursing.

[45]  L-Q Wang,et al.  The expression research of miR-210 in the elderly patients with COPD combined with ischemic stroke. , 2016, European review for medical and pharmacological sciences.

[46]  A. Gopal,et al.  Epidemiology, Traditional and Novel Risk Factors in Coronary Artery Disease. , 2016, Heart failure clinics.